Fluvoxamine for somatoform disorders: An open trial

General Hospital Psychiatry

Volumn 20, Issue 6, 1998, Pages 339-344

  Noyes Jr , Russell ^a   Happel, Rachel L ^a   Muller, Barbara A ^a   Holt, Craig S ^a   Kathol, Roger G ^a   Sieren, Lori R ^a   Amos, James J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NEUROSIS;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; FEMALE; FLUVOXAMINE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; PATIENT COMPLIANCE; SEROTONIN UPTAKE INHIBITORS; SOMATOFORM DISORDERS; TREATMENT OUTCOME;

EID: 0344906128     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-8343(98)00044-9     Document Type: Article

References (50)

1. Kirmayer L.J., Robbins J.M. Three forms of somatization in primary care Prevalence, co-occurrence, and sociodemographic characteristics . J Nerv Ment Dis. 179:1991;647-655.
2. Lipowski Z.J. Somatization The concept and its clinical application . Am J Psychiatry. 145:1988;1358-1368.
3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, American Psychiatric Association, Washington, D.C., 1994.
4. Noyes R., Holt C.S., Kathol R.G. Somatization Diagnosis and management . Arch Fam Med. 4:1995;790-795.
5. Noyes R., Kathol R., Fisher M., et al. The validity of DSM-III-R hypochondriasis. Arch Gen Psychiatry. 50:1993;961-970.
6. Kellner R. Treatment approaches to somatizing and hypochondriacal patients. Kirmayer L.J., Robbins J.M. Current concepts of Somatization Research and Clinical Perspectives . 1991;159-179 American Psychiatric Press, Washington DC.
7. Ward N.G., Bloom V.L., Friedel R.O. The effectiveness of tricyclic antidepressants in the treatment of coexisting pain and depression. Pain. 7:1979;331-341.
8. Onghena P., Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain A meta-analysis of 39 placebo-controlled studies . Pain. 49:1992;205-219.
9. Smith G.R. The epidemiology and treatment of depression when it coexists with somatoform disorders, somatization, or pain. Gen Hosp Psychiatry. 14:1992;265-272.
10. Kroenke K., Spitzer R.L., Williams J.B. Physical symptoms in primary care Predictors of psychiatric disorder and functional impairment . Arch Fam Med. 3:1994;774-779.
11. Hamilton J., Campos R., Creed F. Anxiety, depression and management of medically unexplained symptoms in medical clinics. J Roy Col Physicians London. 30:1996;18-20.
12. Volz H.-P., Stieglitz R.-D., Menges K., Moller H.-J. Somatoform disorders - diagnostic concept, controlled clinical trials, and methodological issues. Pharmacopsychiat. 27:1994;231-237.
13. Escobar J.I. Pharmacological treatment of somatization/hypochondriasis Overview of somatization: Diagnosis, epidemiology, and management . Psychopharmacol Bull. 32:1996;589-596.
14. Kellner R. Psychosomatic Syndromes and Somatic Symptoms. 1991;American Psychiatric Press, Washington, DC.
15. Gruber A.J., Hudson J.I., Pope H.G. The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Psychiatr Clin N Amer. 19:1996;351-369.
16. Klein K.B. Controlled treatment trials in irritable bowel syndrome A critique . Gastroenterology. 95:1988;232-241.
17. Goodnick P.J., Sandoval R. Psychotropic treatment of chronic fatigue syndrome and related disorders. J Clin Psychiatry. 54:1993;13-20.
18. Natelson B.H., Cheu J., Pareja J., et al. Randomized, double-blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. Psychopharmacol. 124:1996;226-230.
19. White K.P., Harth M. An analytical review of 24 controlled clinical trials for fibromyalgia syndrome (FMS). Pain. 64:1996;211-219.
20. Vercoulen J.H.M.M., Swanink C.M.A., Zitman F.G., Vreden S.G.S., Hoofs M.P.E., Fennis J.F.M., Galama J.M.D., van der Meer J.W.M., Bleijenberg G. Randomized, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet. 347:1996;858-861.
21. Goldberg D., Mayskiy M., Mossey C., et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 39:1996;1852-1859.
22. Lindsay P.G., Wyckoff M. The depression-pain syndrome and its response to antidepressants. Psychosomatics. 22:1981;571-577.
23. Stimmel G.L., Escobar J.I. Antidepressants in chronic pain A review of efficacy . Pharmacotherapy. 6:1986;262-267.
24. Walker E.A., Roy-Byrne P.P., Katon W.J., et al. An open trial of nortriptyline in women with chronic pelvic pain. Int J Psychiatry Med. 21:1991;245-252.
25. Zitman F.G., Linssen A.C.G., Edelbroek P.M., et al. Does addition of low-dose flupenthixol enhance the analgesic effects of low-dose amitriptyline in somatoform pain disorder? Pain. 47:1991;25-30.
26. Max M.B., Lynch S.A., Muir J., et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 326:1992;1250-1256.
27. Krishnan K.R.R. Monoamine oxidase inhibitors. Schatzberg A.F., Nemeroff C.B. Textbook of Psychopharmacology. 1995;186-187 American Psychiatric Press, Washington DC.
28. Tollefson G.D. Selective serotonin reuptake inhibitors. Schatzberg A.F., Nemeroff C.B. Textbook of Psychopharmacology. 1995;171 American Psychiatric Press, Washington DC.
29. Hollyman J.A., Freeling P., Pakel E.S., Bhat A., Sedgwick P. Double-blind placebo-controlled trial of amitriptyline among depressed patients in general practice. J Roy Col Gen Pract. 38:1988;393-397.
30. Fallon B.A., Liebowitz M.R., Salman E., et al. Fluoxetine for hypochondriacal patients without major depression. J Clin Psychopharmacol. 13:1993;438-441.
31. Fallon B.A., Schneier F.R., Marshall R., et al. The pharmacotherapy of hypochondriasis. Psychopharmacol Bull. 32:1996;607-611.
32. Wesner R.B., Noyes R. Imipramine an effective treatment for illness phobia. J Affect Dis. 22:1991;43-48.
33. Spitzer R.L., Williams J.B.W., Kroenke K., et al. Utility of a new procedure for diagnosing mental disorders in primary care The PRIME-MD 1000 Study . JAMA. 272:1994;1749-1756.
34. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition, Biometrics Research Department. 1995;New York State Psychiatric Institute, New York, NY.
35. Ballenger J.C., Burrows G.D., DuPont R.L., et al. Alprazolam in panic disorder and agoraphobia Results from a multicenter trial . Arch Gen Psychiatry. 45:1988;403-422.
36. Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised Edition. Department of Health, Education, and Welfare, National Institute of Mental Health, Publication No. ADM76-338, Rockville, MD, 1976.
37. Sheehan D.V. The Anxiety Disease and How to Overcome It. 1983;Scribner, New York.
38. Derogatis LR: Brief Symptom Inventory: Administration, Scoring, and Procedures Manual, Third Edition, National Computer Systems, Minneapolis, MN, 1993.
39. Ware J.E., Snow K.K., Kosinski M., Gandek C. SF-12 Health Survey Manual and Interpretation Guide . 1995;The Health Institute, New England Medical Center, Boston, MA.
40. Quitkin F.M., McGrath P.J., Stewart J.W., Taylor B.P., Klein D.F. Can the effects of antidepressants be observed in the first two weeks of treatment. Neuropsychopharmacology. 15:1996;390-394.
41. Speckens A.E.M., van Hemert A.M., Bolk J.H., et al. The acceptability of psychological treatment in patients with medically unexplained physical symptoms. J Psychosom Res. 39:1995;855-863.
42. Dworkin S.F., Von Korff M., Le Resche L. Multiple pains and psychiatric disturbance. Arch Gen Psychiatry. 47:1990;239-244.
43. Brown F.W., Golding J.M., Smith G.R. Psychiatric comorbidity in primary care somatization disorder. Psychosom Med. 52:1990;445-451.
44. Simon G.E., Von Koff M. Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area study. Am J Psychiatry. 148:1991;1494-1500.
45. Russo J., Katon W., Sullivan M., et al. Severity of somatization and its relationship to psychiatric disorders and personality. Psychosomatics. 35:1994;546-556.
46. Von Korff M., Simon G. The relationship between pain and depression. Br J Psychiatry. 168:(Suppl 30):1996;101-108.
47. Stein G. Drug treatment of the personality disorders. Br J Psychiatry. 161:1992;167-184.
48. Gitlin M.J. Pharmacotherapy and personality disorders Conceptual framework and clinical strategies . J Clin Psychopharmacol. 13:1993;343-353.
49. Creed F., Guthrie E. Techniques for interviewing the somatizing patient. Br J Psychiatry. 162:1993;467-471.
50. Sharpe M., Peveler R., Mayou R. The psychological treatment of patients with functional somatic symptoms A practical guide . J Psychosom Res. 36:1992;515-529.